Humanigen Inc (fka HGENQ)

[nelskof]

Found it in the November presentation:

OWS Regulatory Participation and Expertise

• Interim results (unblinded) shared with OWS
• OWS therapeutic efforts headed by Janet Woodcock, director of the Center for Drug
Evaluation and Research (CDER) at FDA
• Review of all submissions and correspondence to FDA
• OWS FDA SME attendance at company meetings with FDA
• OWS will be included as a Named Contact on all FDA filings
• OWS concurs with expansion of the Phase 3 study and path forward